The clinical significance of occult HBV infection

Annals of Gastroenterology

Volumn 27, Issue 1, 2014, Pages 15-19

  Squadrito, Giovanni ^a   Spinella, Rosaria ^a   Raimondo, Giovanni ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Cirrhosis; Hepatitis B virus; Hepatitis B virus reactivation; Hepatitis B virus transmission; Hepatocellular carcinoma; Occult hepatitis B virus infection

Indexed keywords

HEPATITIS B SURFACE ANTIGEN;

BLOOD TRANSFUSION; CHRONIC LIVER DISEASE; DISEASE COURSE; HEPATITIS B VIRUS; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NONHUMAN; OCCULT HEPATITIS B VIRUS INFECTION; PROTEIN SYNTHESIS; REVIEW; VIRUS INFECTION; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSMISSION; WILD TYPE;

EID: 84890958968     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.
2. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-657.
3. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002;2:479-486.
4. Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunopathol 2013;35:39-52.
5. Alexopoulou A, Dourakis SP, Pandelidaki H, Archimandritis AJ, Karayiannis P. Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine. J Med Virol 2006;78:1043-1046.
6. Hollinger FB, Sood G. Occult hepatitis B virus infection: a covert operation. J Viral Hepat 2010;17:1-15.
7. Pollicino T, Raffa G, Costantino L, et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 2007;45:277-285.
8. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009;51:581-592.
9. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005;42:302-308.
10. Allain JP, Cox L. Challenges in hepatitis B detection among blood donors. Curr Opin Hematol 2011;18:461-466.
11. Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 2008;48:1001-1026.
12. Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. J Hepatol 2009;51:798-809.
13. Stramer SL, Wend U, Candotti D, et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011;364:236-247.
14. Allain JP, Belkhiri D, Vermeulen M, et al. Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology 2009;49:1868-1876.
15. Kannangai R, Vivekanandan P, Netski D, et al. Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J Clin Virol 2007;39:101-105.
16. Chemin I, Guillaud O, Queyron PC, Trepo C. Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J Hepatol 2009;51:824-825.
17. Cheung CK, Lo CM, Man K, Lau GK. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis. Liver Transpl 2010;16:1314-1323.
18. Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010;52:272-279.
19. Coffin CS, Mulrooney-Cousins PM, van Marle G, Roberts JP, Michalak TI, Terrault NA. Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl 2011;17:955-962.
20. Toniutto P, Minisini R, Fabris C, et al. Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: relationship with donor age and fibrosis progression. Clin Transplant 2009;23:184-190.
21. Angelico M, Nardi A, Marianelli T, et al. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study. J Hepatol 2013;58:715-723.
22. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136:699-712.
23. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-528.
24. Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007;39:397-408.
25. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009;90:13-23.
26. Coppola N, Tonziello G, Pisaturo M, et al. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol 2011;83:1909-1916.
27. Grewal J, Dellinger CA, Yung WK. Fatal reactivation of hepatitis B with temozolomide. N Engl J Med 2007;356:1591-1592.
28. Ritchie D, Piekarz RL, Blombery P, et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica 2009;94:1618-1622.
29. Pei SN, Chen CH, Lee CM, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010;89:255-262.
30. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605-611.
31. Onozawa M, Hashino S, Izumiyama K, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005;79:616-619.
32. Viganò M, Vener C, Lampertico P, et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant 2011;46:125-131.
33. Raimondo G, Navarra G, Mondello S, et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 2008;48:743-746.
34. Blackberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 2000;33:992-997.
35. Yuki N, Nagaoka T, Yamashiro M, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003;37:1172-1179.
36. Mulrooney-Cousins PM, Michalak TI. Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J Gastroenterol 2007; 13:5682-5686.
37. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22-26.
38. Covolo L, Pollicino T, Raimondo G, Donato F. Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig Liver Dis 2013;45:238-244.
39. Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol 2013;59:696-700.
40. Raimondo G, Pollicino T, Squadrito G. What is the clinical impact of occult hepatitis B virus infection? Lancet 2005;365:638-640.
41. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004;127(5 Suppl 1):S56-S61.
42. Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis 2011;32:1122-1132.
43. Squadrito G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006;106:1326-1330.
44. Obika M, Shinji T, Fujioka S, et al. Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study. Intervirology 2008;51:59-68.
45. Tamori A, Hayashi T, Shinzaki M, et al. Frequent detection of hepatitis B virus DNA in hepatocellular carcinoma of patients with sustained virologic response for hepatitis C virus. J Med Virol 2009;81:1009-1014.
46. Wong DK, Huang FY, Lai CL, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 2011;54:829-836.
47. Corradini E, Ferrara F, Pollicino T, et al. Disease progression and liver cancer in the ferroportin disease. Gut 2007;56:1030-1032.
48. Pollicino T, Vegetti A, Saitta C, et al. Hepatitis B virus DNA integration in tumour tissue of a non-cirrhotic HFE-haemochromatosis patient with hepatocellular carcinoma. J Hepatol 2013;58:190-193.
49. Chang ML, Lin YJ, Chang CJ, et al. Occult and overt HBV coinfections independently predict postoperative prognosis in HCVassociated hepatocellular carcinoma. PLoS One 2013;8:e64891.
50. Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int 2012;32:231-240.